Advertisement

Rib-X Pharmaceuticals Inc., an antibiotics company in New Haven, Conn., has begun a Phase 2b clinical trial of its treatments for acute bacterial skin and skin structure infections (ABSSSI).

The treatments – delafloxacin, linezolid and vancomycin – will be tested on 240 participants to help the company design Phase 3 clinical studies. The Phase 2b study is expected to show responses of the treatment on cellulitis/erysipelas, wound infection, major cutaneous abscess or burn infection.

SOURCE

Advertisement
Advertisement